- Home
- Cardiology
- ARISTOTLE Trial Results Reinforce Apixaban’s Role in Modern Anticoagulation

1d3 min read
Medical Article
Background Atrial fibrillation (AF) is a prevalent cardiac arrhythmia associated with an increased risk of stroke. Warfarin, a vitamin K antagonist, has long been the standard oral anticoagulant for stroke prevention in AF. However, its use is hindered by frequent monitoring requirements, dietary restrictions, and bleeding risks. Apixaban, a novel

ARISTOTLE Trial Results Reinforce Apixaban’s Role in Modern Anticoagulation
Similar Content

Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure
150 Reached

ACC, AHA and ESC Recommendations for Heart Failure Management
2323 Reached29 Comments2 Likes

Catheter Ablation for Atrial Fibrillation with HF
691 Reached

Patient with History of Atrial Fibrillation
519 Reached3 Likes

FOURIER Trial: Efficacy of Evolocumab in Managing Cardiovascular Events
563 Reached3 Comments